Search
IFx-Hu2.0
go.drugbank.com/drugs/DB18396InvestigationalIFx-Hu2.0 is an investigational cancer vaccine. It is composed of plasmid DNA encoding the streptococcal membrane protein, Emm55, contained within a cationic polymer.
NDX-3315
go.drugbank.com/drugs/DB18671InvestigationalNDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled [heparin].
Olvimulogene nanivacirepvec
go.drugbank.com/drugs/DB16268InvestigationalOlvimulogene nanivacirepvec is under investigation in clinical trial NCT01443260 (A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis).
VAD-044
go.drugbank.com/drugs/DB17697InvestigationalVAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]
Daglutril
go.drugbank.com/drugs/DB05796InvestigationalDaglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.
N-Acetyl-glucosamine thiazoline
go.drugbank.com/drugs/DB03747ExperimentalN-Acetyl-glucosamine thiazoline (NAG-thiazoline) is an analog of the oxazolinium bicyclic intermediate leading from N-acetylglucosamine to 1,6-anhydro-N-acetylmuramic acid.
8-azaguanine
go.drugbank.com/drugs/DB01667ExperimentalIt functions as an antimetabolite and is easily incorporated into ribonucleic acids.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates(S)-camphor
go.drugbank.com/drugs/DB11345ApprovedIt has been used as a nasal decongestant and cough suppressant, and has been topically applied due to its antipruritic, analgesic, and counterirritant properties [A33086].
Mixtures: U Ice Cold, U Ice ColdDT-DEC01
go.drugbank.com/drugs/DB19433ExperimentalDT-DEC01 is a novel Dystrophin Expressing Chimeric (DEC) cell therapy being investigated by Dystrogen Therapeutics Corporation.
Sorbitan tristearate
go.drugbank.com/drugs/DB20134ExperimentalSorbitan tristearate has a monoisotopic molecular weight of 962.85 Da.